{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:acasunlimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00259233: Not Applicable Interventional Completed Obesity
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02565758: Phase 1 Interventional Completed Advanced Solid Tumors
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:casdozokitug [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:efbalropendekin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04656418: Phase 3 Interventional Completed Hereditary Angioedema
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04317040: Phase 3 Interventional Completed Coronavirus Disease 2019 (COVID-19)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04344158: Phase 3 Interventional Active, not recruiting Advanced Hepatocellular Carcinoma (HCC)
(2020)
Source URL:
Class:
PROTEIN
